Recently, the snake-arm single-port surgical robot developed by Beijing Daxing-based company Beijing Surgerii Robotics Co Ltd (Surgerii Robotics) successfully assisted in completing the world’s first intercontinental remote thoracic surgery.

This milestone marks the first time Chinese original high-end medical equipment has entered European clinical practice, breaking the technological monopoly held by Europe and the US. The robot has submitted for the EU’s CE certification and holds over 800 patent applications, filling a gap in China’s single-port endoscopy field.

A surgical robot developed and produced by Surgerii Robotics. [Photo/Beijing Youth Daily]

As a national-level biomedical industrial base, the Daxing Biomedical Industry Base hosts more than 800 enterprises, including 12 national testing institutions and 292 high-tech companies. The base boasts 821 approved pharmaceuticals and over 1,000 medical devices, centered around three main pillars: vaccines, traditional Chinese medicine, and high-end medical devices, alongside five cutting-edge sectors such as cell and gene therapy, medical aesthetics, and synthetic biology.

Surgerii Robotics is a high-tech company dedicated to the independent R&D, production, and commercialization of minimally invasive laparoscopic surgical robot systems and related instruments. It has collaborated with top hospitals to complete over 40 innovative surgical procedures. 

Other standout achievements by companies in the park include Beijing M&B Electronic Instruments’ portable monitors, now widely used in top-tier hospitals across the country, and its AED devices deployed in multiple locations; Beijing WeHand Bio’s “Mulberry Twig Alkaloids Tablets”, the world’s first plant-derived natural hypoglycemic drug benefiting countless patients; and Beijing Echo Biotech’s establishment of China’s first GMP-standard exosome production facility.

The enterprises’ growth benefits from Beijing’s industrial ecosystem and policy support. Municipal and district governments provide full-chain assistance through green channels for innovative drug and device approvals, industry fund investments, and talent policies.

Thanks to Beijing’s fast-track approvals, financial backing from both municipal and district funds, abundant clinical resources, and close links with leading research institutes, local tech companies like M&B Electronic Instruments and Beijing WeHand Bio have accelerated product delivery and advanced innovative drug development.

Looking ahead, Daxing Biomedical Industry Base plans to further cultivate technology and innovation, join forces with resident enterprises to boost high-quality development of the capital’s biomedical industry, and contribute to the innovation-driven upgrading of China’s biomedical sector.